收费全文 | 53837篇 |
免费 | 3467篇 |
国内免费 | 242篇 |
耳鼻咽喉 | 545篇 |
儿科学 | 1051篇 |
妇产科学 | 704篇 |
基础医学 | 7068篇 |
口腔科学 | 1183篇 |
临床医学 | 5540篇 |
内科学 | 11808篇 |
皮肤病学 | 1047篇 |
神经病学 | 6271篇 |
特种医学 | 2634篇 |
外科学 | 8829篇 |
综合类 | 354篇 |
一般理论 | 13篇 |
预防医学 | 2743篇 |
眼科学 | 803篇 |
药学 | 3261篇 |
中国医学 | 77篇 |
肿瘤学 | 3615篇 |
2023年 | 427篇 |
2022年 | 557篇 |
2021年 | 1475篇 |
2020年 | 894篇 |
2019年 | 1342篇 |
2018年 | 1513篇 |
2017年 | 1183篇 |
2016年 | 1423篇 |
2015年 | 1639篇 |
2014年 | 2071篇 |
2013年 | 2588篇 |
2012年 | 4116篇 |
2011年 | 4128篇 |
2010年 | 2454篇 |
2009年 | 2206篇 |
2008年 | 3571篇 |
2007年 | 3638篇 |
2006年 | 3402篇 |
2005年 | 3346篇 |
2004年 | 2969篇 |
2003年 | 2841篇 |
2002年 | 2563篇 |
2001年 | 620篇 |
2000年 | 501篇 |
1999年 | 536篇 |
1998年 | 540篇 |
1997年 | 411篇 |
1996年 | 330篇 |
1995年 | 271篇 |
1994年 | 278篇 |
1993年 | 217篇 |
1992年 | 257篇 |
1991年 | 227篇 |
1990年 | 188篇 |
1989年 | 191篇 |
1988年 | 172篇 |
1987年 | 150篇 |
1986年 | 169篇 |
1985年 | 149篇 |
1984年 | 163篇 |
1983年 | 149篇 |
1982年 | 128篇 |
1981年 | 103篇 |
1980年 | 88篇 |
1979年 | 120篇 |
1978年 | 93篇 |
1977年 | 91篇 |
1976年 | 99篇 |
1975年 | 85篇 |
1974年 | 96篇 |
Background
Hyperglycaemia is common in patients with acute brain injury admitted to an intensive care unit (ICU). Many studies have found associations between development of hyperglycaemia and increased mortality in hospitalised patients. However, the optimal target for blood glucose control is unknown. We want to conduct a systematic review with meta-analysis and trial sequential analysis to explore the beneficial and harmful effects of restrictive versus liberal glucose control on patient outcomes in adults with severe acute brain injury.Methods
We will systematically search medical databases including CENTRAL, Embase, MEDLINE and trial registries. We will search the following websites for ongoing or unpublished trials: http://www.controlled-trials.com/ , http://www.clinicaltrials.gov/ , www.eudraCT.com , http://centerwatch.com/ , The Cochrane Library's CENTRAL, PubMed, EMBASE, Science Citation Index Expanded and CINAHL. Two authors will independently review and select trials and extract data. We will include randomised trials comparing levels of glucose control in our analyses and observational studies will be included to address potential harms. The primary outcomes are defined as all-cause mortality, functional outcome and health-related quality of life. Secondary outcomes include serious adverse events including hypoglycaemia, length of ICU stay and duration of mechanical ventilation, and explorative outcomes including intracranial pressure and infection. Trial Sequential Analysis will be used to investigate the risk of type I error due to repetitive testing and to further explore imprecision. Quality of trials will be evaluated using the Cochrane Risk of Bias tool, and quality of evidence will be assessed using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach.Discussion
The results of the systematic review will be disseminated through peer-reviewed publication. With the review, we hope to inform future randomised clinical trials and improve clinical practice. 相似文献Methods: Two previously published datasets (n?=?153 and n?=?641, respectively) from outpatient neuropsychological evaluations were used to test Dunham and Denney’s algorithm, and to assess concordance of failure rates with the Test of Memory Malingering and the forced choice measure of the California Verbal Learning Test, two commonly used performance validity tests.
Results: In both datasets, none of the four cutoff scores for failure on the MSVT (70%, 75%, 80%, or 85%) identified a poor validity group with proportionally aligned failure rates on other freestanding measures of performance validity. Additionally, the protocols with probable impairment did not differ from those with poor validity on cognitive measures.
Conclusions: Despite what appeared to be a promising approach to evaluating failure on the easy MSVT subtests when clinical data are unavailable (as recommended in the advanced interpretation program, or advanced interpretation [AI], of the MSVT), the current findings indicate the AI remains the gold standard for doing so. Future research should build on this effort to address shortcomings in measures of effort in neuropsychological evaluations. 相似文献
Objective
Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.Methods
Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.Results
In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.Conclusions
Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection. 相似文献![点击此处可从《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》网站下载免费的PDF全文](/ch/ext_images/free.gif)